{"title":"突破感染后SARS-CoV-2清除与健康和快乐细胞相关","authors":"Marc Veldhoen, Antonio Bertoletti","doi":"10.1111/imcb.12667","DOIUrl":null,"url":null,"abstract":"<p><i>Immunology & Cell Biology</i> 2023; <b>101</b>: 672; https://doi.org/10.1111/imcb.12667</p><p>Correction to: <i>Immunology & Cell Biology</i> 2023; https://doi.org/10.1111/imcb.12654</p><p>Conflicts of Interest were omitted from this article. This information appears below. The authors apologize for this error.</p><p>A Bertoletti reports a pending patent for a method to monitor SARS-CoV-2-specific T cells in biological samples. He is also co-founder and owns shares in (a) LION TCR, a biotech company developing T cell therapy against virus-related cancers, and (b) T-cell Diagnostic, a company providing immunological monitoring in clinical samples.</p>","PeriodicalId":179,"journal":{"name":"Immunology & Cell Biology","volume":"101 7","pages":"672"},"PeriodicalIF":3.0000,"publicationDate":"2023-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/imcb.12667","citationCount":"0","resultStr":"{\"title\":\"SARS-CoV-2 clearance after breakthrough infection correlates with fit and happy cells\",\"authors\":\"Marc Veldhoen, Antonio Bertoletti\",\"doi\":\"10.1111/imcb.12667\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><i>Immunology & Cell Biology</i> 2023; <b>101</b>: 672; https://doi.org/10.1111/imcb.12667</p><p>Correction to: <i>Immunology & Cell Biology</i> 2023; https://doi.org/10.1111/imcb.12654</p><p>Conflicts of Interest were omitted from this article. This information appears below. The authors apologize for this error.</p><p>A Bertoletti reports a pending patent for a method to monitor SARS-CoV-2-specific T cells in biological samples. He is also co-founder and owns shares in (a) LION TCR, a biotech company developing T cell therapy against virus-related cancers, and (b) T-cell Diagnostic, a company providing immunological monitoring in clinical samples.</p>\",\"PeriodicalId\":179,\"journal\":{\"name\":\"Immunology & Cell Biology\",\"volume\":\"101 7\",\"pages\":\"672\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2023-07-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/imcb.12667\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Immunology & Cell Biology\",\"FirstCategoryId\":\"2\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/imcb.12667\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CELL BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunology & Cell Biology","FirstCategoryId":"2","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/imcb.12667","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
免疫学,细胞生物学2023;101: 672;https://doi.org/10.1111/imcb.12667Correction到:免疫学&细胞生物学2023;https://doi.org/10.1111/imcb.12654Conflicts of Interest在本文中被省略。该信息如下所示。作者为这个错误道歉。Bertoletti报告了一项正在申请中的专利，该专利用于监测生物样本中sars - cov -2特异性T细胞的方法。他也是(a) LION TCR(开发针对病毒相关癌症的T细胞疗法的生物技术公司)和(b) T细胞诊断(提供临床样本免疫监测的公司)的联合创始人并拥有股份。
Correction to: Immunology & Cell Biology 2023; https://doi.org/10.1111/imcb.12654
Conflicts of Interest were omitted from this article. This information appears below. The authors apologize for this error.
A Bertoletti reports a pending patent for a method to monitor SARS-CoV-2-specific T cells in biological samples. He is also co-founder and owns shares in (a) LION TCR, a biotech company developing T cell therapy against virus-related cancers, and (b) T-cell Diagnostic, a company providing immunological monitoring in clinical samples.
期刊介绍：
The Australasian Society for Immunology Incorporated (ASI) was created by the amalgamation in 1991 of the Australian Society for Immunology, formed in 1970, and the New Zealand Society for Immunology, formed in 1975. The aim of the Society is to encourage and support the discipline of immunology in the Australasian region. It is a broadly based Society, embracing clinical and experimental, cellular and molecular immunology in humans and animals. The Society provides a network for the exchange of information and for collaboration within Australia, New Zealand and overseas. ASI members have been prominent in advancing biological and medical research worldwide. We seek to encourage the study of immunology in Australia and New Zealand and are active in introducing young scientists to the discipline.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
